Accordingly, patients with biochemical recurrence having the lowest PSA levels prior to PSMA PET/CT had the lowest detection rate (55.1%) compared to patients with persistent (75%) or primary prostate cancer (100%). The gene discussed is PROS1; the disease is prostate cancer.